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A polymer-grafted liposomal formulation that has the potential to be developed for aerosolic pulmonary delivery of vasoactive intestinal
peptide (VIP), a potent vasodilatory neuropeptide, is described. As VIP is prone to rapid proteolytic degradation in the microenvironment of the
lung a proper delivery system is required to increase the half-life and bioavailability of the peptide. Here we investigate structural parameters of
unilamellar liposomes composed of palmitoyl-oleoyl-phosphatidylcholine, lyso-stearyl-phosphatidylglycerol and distearyl-phosphatidyl-
ethanolamine covalently linked to polyethylene glycol 2000, and report on VIP–lipid interaction mechanisms. We found that the cationic VIP
is efficiently entrapped by the negatively charged spherical liposomes and becomes converted to an amphipathic α-helix. By fluorescence
spectroscopy using single Trp-modified VIP we could show that VIP is closely associated to the membrane. Our data suggest that the N-terminal
random-coiled domain is embedded in the interfacial headgroup region of the phospholipid bilayer. By doing so, neither the bilayer thickness of
the lipid membrane nor the mobility of the phospholipid acyl chains are affected as shown by small angle X-ray scattering and electron spin
resonance spectroscopy. Finally, in an ex vivo lung arterial model system we found that liposomal-associated VIP is recognized by its receptors to
induce vasodilatory effects with comparable high relaxation efficiency as free VIP but with a significantly retarded dilatation kinetics. In
conclusion, we have designed and characterized a liposomal formulation that is qualified to entrap biologically active VIP and displays structural
features to be considered for delivery of VIP to the lung.
© 2006 Elsevier B.V. All rights reserved.Keywords: Polyethlene glycolated liposome; Sterically stabilized liposome; Nanostructure; Amphipathic peptide; Peptide–lipid interaction1. Introduction
Vasoactive intestinal peptide (VIP) is a cationic mammalian
neuropeptide that exerts multiple biological functions including
systemic and pulmonary vasodilation, bronchodilatation, anti-
inflammatory and immunomodulatory effects [1–3]. The
function of VIP is mediated by a specific receptor class,
VPAC1 and VPAC2, and both receptors being highly expressed
in the bronchial tree and in the pulmonary vasculature [4,5].
This contributes to the fact that VIP can be considered as a
therapeutic agent for severe lung diseases such as primary
pulmonary hypertension (PPH) or chronic obstructive pulmon-⁎ Corresponding author. Tel: +43 316 4120 305; fax: +43 316 4120 390.
E-mail address: ruth.prassl@oeaw.ac.at (R. Prassl).
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doi:10.1016/j.bbamem.2006.11.017ary disease (COPD). In PPH the blood pressure in the
pulmonary artery rises far above normal levels. Untreated, the
median period of survival for PPH is 3 years following
diagnosis [6]. Common to all PPH patients is the lack of VIP in
serum, together with an upregulation of VIP receptors in the
lung [6]. It has been shown that aerosolic applications of VIP
can halt the progression of the disease and may relieve the
symptoms. However, the clinical application of VIP is severely
limited by the fact that VIP is prone to rapid proteolytic
digestion and inactivation by neutral endopeptidases, reducing
the efficiency and bioavailability of the peptide [7–9]. For these
reasons it is an ongoing need to establish a proper delivery
system for aerosolic application of VIP.
The structural versatility of lipid species and the use of lipid
mixtures and co-additives make liposomes excellent carriers for
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[10–13]. In particular, polymer surface coated liposomes,
known as sterically stabilized liposomes have been shown to
exhibit a longer life-time in the circulation [14–20].
To date most liposomal formulations have been designed for
intravenous application and delivery of small molecules.
Nonetheless, the way should also be opened for the delivery
of peptides by alternate administration routes such as
pulmonary delivery by inhalation.
However, to act as potent carrier for peptides to the lung, the
delivery system has to meet certain criteria. First, the liposomal
formulation has to be stable and of optimal size to reach the
lower bronchioles [21]. Second, the liposomes have to
accommodate sufficient amounts of peptide and shield their
payload from enzymatic degradation in the pulmonary
microenvironment.
In this study we have used a ternary lipid mixture that self-
assembles to form sterically stabilized unilamellar liposomes.
The liposomes are composed of phosphatidylcholine as lipid
matrix combined with polyethyleneglycol-grafted phosphati-
dylethanolamine and lyso-phosphatidylglycerol. Since this
formulation has not been described so far we aimed to
characterize it and to address the question of its suitability as
peptide carrier. Accordingly, it was important to examine the
impact of peptide loading both on particle stability and integrity.
In particular, the structural features of the self-associated
peptide in the presence of lipids and the interaction mechanisms
with the lipid bilayer were investigated in detail. These
structural data might also be important in respect to receptor
binding and cellular processes [5,22]. Finally, the biological
response of living lung arteries to liposomal-associated VIP was
tested in terms of vasorelaxation activities.
2. Materials and methods
Palmitoyl-oleoyl-phosphatidylcholine (POPC), lyso-stearyl-phosphatidyl-
glycerol (lyso-PG) and polyethyleneglycol conjugated distearyl-phosphatidy-
lethanolamine (DSPE-PEG2000) were purchased from Avanti Polar Lipids
(Alabaster, AL).
Acetylcholine chloride, L-phenylephrine hydrochloride and all other
chemicals were purchased from Sigma-Aldrich, Vienna, Austria.
VIP (amino-acid sequence HSDAVFTDNYTRLRKQMAVKKYLNSILN-
NH2), VIPC-terminally labeledwith the fluorescent marker Cy3 (VIP(Cy3)) and
three different tryptophan (Trp) modified VIP species, namely N-terminally
modified VIP (Trp1VIP), C-terminally modified VIP (Trp29VIP) and Trp inserted
at position 16 of the amino acid sequence of VIP (Trp16VIP) were synthesized by
piCHEM (Graz, Austria) using FMOC-solid-phase peptide synthesis metho-
dology (FMOC-SPPS). The peptides were purified by RP-HPLC.
2.1. Nanoparticle preparation
Stock solutions of DSPE-PEG2000, lyso-PG and POPC were prepared in
chloroform and chloroform:methanol 9:1 and 2:1 (v/v), respectively. Aliquot
amounts of lipid stock solutions were mixed to yield a molar ratio of DSPE-PEG-
2000: lyso-PG: POPC of 5: 38: 57 mol% with a total lipid content of 30 mg. The
organic solvents were evaporated under a stream of nitrogen. Residual traces of
solvent were removed in high vacuum overnight. The dry lipid film was
suspended in 1 mL buffer consisting of 10 mM Tris–HCl, pH: 7.4 (Tris-buffer)
and hydrated at 40 °C for 60 min with repeated vortexing. For peptide loading
hydration was performed with 1 mL Tris-buffer containing 0.5 mg VIP
(corresponding to a molar phospholipid to VIP ratio of 250:1). Peptide loadingwas quantified using fluorescent labeled peptide (VIP(Cy3)) and separation by
gel filtration chromatography using a Sephadex G 75 column (Amersham
Biosciences, Uppsala, Sweden). VIP(Cy3) eluted as a single band together with
the liposomes. In comparison, free VIP(Cy3) used as control, did not show a
single band, but smeared along the column.
When appropriate, lipid suspensions were extruded 21 times through
polycarbonate filters (Millipore, Vienna Austria) with 100 nm pore size using a
LiposoFast pneumatic extruder (Avestin, Inc. Ottawa, ON). If not stated
otherwise, non-extruded liposomes were used for the experiments.
Phospholipid concentration was determined by a modified Bartlett inorganic
phosphate assay [23].
2.2. Photon correlation spectroscopy (PCS)
The particle size of the liposomes was determined by photon correlation
spectroscopy (PCS) with a Zetasizer 3000 HSA (Malvern Instruments,
Herrenberg, Germany). The instrument was equipped with a 10 mW helium-
neon laser operating at 632.8 nm. The scattered light was detected at an angle of
90° by a photon counting avalanche photodiode detector coupled to a correlator.
Particle size is derived by an auto-correlation function. The results are expressed
as Z-average, which is the harmonic-intensity averaged particle diameter. The
width of the size distribution is given by the polydispersity index (PDI).
Empty and VIP-loaded liposomes before and after extrusion were diluted to
a concentration of 0.03 mg/mL with Tris-buffer, which was previously filtered
through a disposable 0.02 μm membrane filter unit (Anotop 25, Whatman
International Ltd., Maidstone, UK). The measurements were performed at room
temperature.
2.3. Transmission electron microscopy (TEM)
For electron microscopy the liposomes were fixed with 1% aqueous OsO4
over night at 4 °C. A fine, cloudy precipitate formed and the clear supernatant
was carefully removed. Absolute (100%) ethanol was added and after 1–2 h
the precipitate condensed to form a loose pellet. The ethanol was replaced by
propylene oxide as intermedium, and the pellet passed through increasing
concentrations of epon in propylene oxide. The pellet was finally polymerized
by incubation with epon at 60 °C for 24 h. Ultrathin sections of about 90 nm
thickness were cut from the epon-embedded nanoparticle block, and double-
stained with uranyl acetate and lead citrate. The sections were viewed in a
Zeiss EM 10 electron microscope, images being recorded on Kodak Electron
Microscope Film 4489.
2.4. Small angle X-ray scattering (SAXS)
Small angle X-ray scattering (SAXS) measurements were performed with an
integrated SWAXS camera system (HECUS X-ray Systems, Graz, Austria)
equipped with a semitransparent Ni-filtered beam-stop, a position-sensitive
detector and a data collection unit. The camera was attached to a conventional
Cu-anode generator (Seifert-GE ID 3003, Ahrensburg, Germany) operated at 2
kW. SAXS patterns were recorded in a q-range between 0.088 nm−1 and
3.0 nm−1, where q=(4π sin θ)/λ is the scattering vector, 2θ the scattering angle
and λ=0.154 nm the wavelength of the X-ray beam. The data were buffer
background corrected, normalized to intensity and corrected for slit collimation
geometry. Indirect Fourier Transform of the data was performedwith the program
GIFT [24]. The cross-sectional structure of the bilayer was analyzed by
deconvolution of the cross-section correlation function pt(r). Information about
the axial thickness of the phospholipid bilayer was derived from the maximum of
the pt(r) function.
SAXS measurements were performed at 20 °C with an exposure time of 1 h
on empty and VIP (0.15 mM) loaded liposomes before and after extrusion at a
lipid concentration of 38.5 mM.
2.5. Circular dichroism and secondary structure prediction
Circular dichroism (CD) spectra were recorded on a JASCO J-715
spectropolarimeter (Jasco Inc., MD, USA) in the far-UV range from 180 to
250 nm using a quartz cuvette with 2 mm cell length. A bandwidth of 1 nm with
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acquisition of spectra. The average of five accumulations was taken for data
evaluation. The recorded spectra for free VIP and liposomal-associated VIP
(0.15 mM) were background corrected for Tris-buffer and empty liposomes,
respectively. Data are expressed as the mean molar ellipticity [θ] (deg cm2
dmol−1) at a given wavelength defined as:
H½  ¼ Hobs
10dcdl
ð1Þ
where Θobs is the measured ellipticity in degrees, c is the peptide residue
concentration in mol/L, and l is the length of the light path in cm.
The ellipticity data were analyzed for secondary structure with the use of
the Web service “DichroWeb” applying the analysis algorithm CDSSTR
[25,26].
The amino acid sequence of VIP was subjected to an automated secondary
structure prediction service, namely PSIPRED [27,28] that is based on position-
sensitive scoring matrices.
2.6. Fluorescence spectroscopy
Fluorescence measurements were performed on a SPEX FLUOROMAX-3
fluorescence spectrophotometer (Jobin Yvon Horiba, Longjumeau Cedex,
France) using a 10 mm×10 mm fluorescence quartz cuvette.
As Trp-modified VIP also contains tyrosine and phenylalanine residues, the
excitation wavelength has to be chosen carefully to avoid the excitation of these
other two aromatic amino acids. On this account tryptophan was selectively
excited at 292 nmwith a band width of 5 nm and an integration time of 0.1 s. The
emission wavelengths were assessed between 320 and 380 nm.
Experiments were performed at room temperature with 10 μM free Trp-
VIP in Tris-buffer or in a solution of PEG2000, respectively. Liposomal-
associated Trp1VIP, Trp16VIP and Trp29VIP were measured in Tris-buffer.
The background intensities of Tris-buffer and empty liposomes, respectively,
were subtracted before determination of emission maxima and fluorescence
intensities.
2.6.1. Acrylamide quenching of Trp fluorescence
Aliquots of a 3 M acrylamide stock solution were added to 10 μM free Trp-
VIP in Tris-buffer or PEG2000 solution or to liposomal-associated Trp1VIP,
Trp16VIP and Trp29VIP in Tris-buffer, respectively. The acrylamide concentra-
tion was varied between 0.02 and 0.15 M. The experimental conditions were as
described above.
The quenching data were analyzed with the Stern–Volmer equation
I0
I
¼ Ka* Q½  þ 1 ð2Þ
where I0 is the fluorescence intensity at zero quencher concentration, I is the
intensity at a given quencher concentration Q and Ka is the Stern–Volmer
quenching constant of the accessible fraction.
The measured fluorescence intensities were corrected for the volume
increase and the inner filter effect on the excitation beam caused by acrylamide.
The inner filter effect was corrected using the formula
Icorr ¼ Iabs*anti log ðAex þ AemÞ2
 
ð3Þ
where Icorr is the corrected fluorescence intensity and Iabs the measured one. Aex
and Aem are the absorption values for acrylamide at different concentrations at
the excitation and emission wavelengths, respectively.
For the calculation of the Stern–Volmer quenching constants the intensity
values were taken at the wavelength of the emission maximum, which was
different for free and liposomal-associated VIP.
2.7. Electron spin resonance spectroscopy (ESR)
Liposomes were prepared as described above, but additionally contained
5-doxylstearic acid (5-DSA), a spin labeled fatty acid that probes the acyl
chain region of the liposomes near the phospholipid headgoup. The molarratio of spin label to total phospholipid was 1:60. The ESR measurements
were performed with empty, Trp–VIP- and VIP-loaded liposomes.
The spectra were recorded at room temperature on an X-band ECS 106
spectrometer (Bruker, Rheinstetten, Germany) with a modulation amplitude of
1.2 G and a sweep width of the static field of 100 G.
Changes in the motional dynamics and relative orientation of the spin-probe
were examined by evaluation of the outer and inner hyperfine splittings 2A|| and
2A⊥ and calculation of the corresponding order parameters S (Eq. (4) and (5))
S ¼ faðAP  A8Þ
Az  0; 5ðAx þ AzÞ ð4Þ
where fa is the polarity correction factor derived for ESR crystal data for Ax, Ay
and Az
fa ¼ Ax þ Ay þ AzAP þ 2A8 ð5Þ
2.8. Ex vivo lung arterial model system
Adult male Sprague–Dawley rats (Abteilung für Labortierkunde und
Labortiergenetik, Medical University of Vienna, Himberg, Austria) weighing
250–280 g were used for the extraction/preparation of pulmonary arteries. All
procedures were performed according to current national legislation. The
animals were anaesthetized, lungs were excised en bloc and pinned on wax in
a petri dish containing cold Krebs–Henseleit buffer (KH-buffer) in an
orientation that facilitated identification of the pulmonary arteries (originating
from the right ventricle). The pulmonary arterial tree was rapidly dissected
from the lung parenchyma. The common pulmonary artery and the left and
right extrapulmonary artery segments were opened longitudinally and divided
into two pulmonary artery preparations. The preparations were cut as zigzag
segments (to achieve strips of approximately 1.3 to 1.5 cm length) and
mounted in thermostatically controlled (37 °C) organ baths, which contained
9 ml of KH-buffer (pH=7.4) gassed with 95% O2 and 5% CO2. The arterial
strips were equilibrated for 2–3 h in the organ baths. The KH-buffer was
renewed three times during this process. The activity of the arterial strips
under investigation was recorded isotonically under a resting load of 1 g. The
arterial segments were viable for at least 4–5 h under these conditions. The
mechanical signals (artery extension and contraction) were processed by
bridge amplifiers (Hugo Sachs Elektronik, Germany) and recorded on ink
writers.
At the beginning of each experiment the arterial reactivity was examined.
This was done by precontraction of the isolated pulmonary arteries with a
submaximal concentration (EC80) of the α1-adrenoceptor agonist L-pheny-
lephrine hydrochloride (Phe; 0.1 μM). Thereafter, either 100 nM free VIP or
equimolar amounts of liposomal-VIP were added and the relaxation efficiency
and the time period to attain the maximal relaxation were recorded. For direct
comparison, experimental cycles were performed by alternate use of free or
liposomal-VIP intermitted by extensive washing.
At the end of each experiment acetylcholine (1 μM) was added to
control the viability of the arterial strips. In case of an acetylcholine-
induced relaxation of more than 60% of the Phe-induced precontraction,
the arteries were classified as intact. Only these experiments were included
into the study. Empty liposomes used as a control had no impact on
precontraction- or relaxation- behavior of the lung arteries. The fact that
the survival rate of the arteries was not affected by liposomes indicates that
at the given concentration liposomes have no cytotoxic effects on lung
arteries.
2.9. Data and statistical analysis
Data are expressed as means ±SEM. The number of independent experiments
is given as n.
For the statistic evaluation a Student's t-test was used. Statistical signi-
ficance was assumed at p<0.05.
Data analysis of the lung arterial experiments was performed as follows. The
pre-contraction by Phe was taken as 100%. The vasorelaxation induced by
Fig. 1. Transmission electron microscopic image of extruded liposomes. The
liposomes were osmium-fixed, epon-embedded and ultrathin sections, about
90 nm thick, were cut and uranyl/lead stained. Original magnification 80000×.
Calibration bar: 100 nm.
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These data were transferred to a data evaluation program (SigmaPlot 8.02, SPSS
Inc.) for plotting. Statistical analysis was performed with a paired sample t-test
on consecutive exposures with free- and liposomal-VIP on the very same
arteries.
Statistics were performed using the programMINITAB 13.31 (MinTab Inc.).
3. Results
3.1. Liposomal size distribution
A ternary mixture of zwitterionic PC with a saturated and an
unsaturated acyl chain (POPC), anionic lyso-stearylphosphati-
dylglycerol (lyso-PG) and distearylphosphatidyl-ethanolamine
with covalently linked polyethylene glycol with a molecular
weight of 2000 (DSPE-PEG2000) was used for the preparation
of liposomes by the thin film rehydration method. Hydration of
the dry lipid film without further size extrusion yields
unilamellar liposomes of two size populations. The main
population comprises more than 95% of the particles with a
mean hydrodynamic diameter of 180±10 nm (n=7). Up to 5%
of the particles in the suspension aremuch larger in size, between
320 and 550 nm. The PDI values varied between 0.2 and 0.5.
Subsequent size extrusion led to a highly homogeneous particle
size distribution and a remarkable decrease in PDI values. A
single population with a mean diameter of 91±3 nm (n=14) and
PDI values between 0.1 and 0.2 was obtained.
The mean particle diameter of VIP-loaded liposomes was not
significantly different (90±3 nm ; p>0.5 for n=5) and the PDI-
values varied between 0.1 and 0.3.
To check particle stability the PCS measurements were
repeated over a certain period of time. There was no significant
change in mean diameter (p=0.94) and only a small broadening
in size distribution, characterized by an increase of SEM and
PDI values, was found. After a storage period of 12 weeks at 4
°C, the mean particle diameter was 91±8 nm (n=3) and the PDI
values varied between 0.2 and 0.4.
3.2. Liposome morphology
To obtain additional information on particle morphology,
transmission electron microscopy (TEM) was performed. TEM
images taken from uranyl/lead contrasted ultrathin sections of
extruded liposomes basically show hollow spheres with a size
of approximately 80–100 nm (Fig. 1). These values correlated
well with the results from PCS.
The smaller spherical particles seen in the images are
sectioning artifacts produced by the thin cutting procedure,
when only the cap of the particle is included within the section.
Nevertheless, in all images a small proportion of wormlike,
tubular particles are observed which represent a miniscule
population of non-spheroidal nanoparticles.
3.3. Bilayer organization of liposomes
X-ray scattering experiments were performed to determine
the lamellar organization of the particles. The scattering patterns
of both, non-extruded and extruded liposomes, showed thesame characteristics. We could see neither Bragg peaks,
characteristic for multilamellar liposomes, nor any indication
of the formation of a non-lamellar phase (Fig. 2A). Indeed, the
scattering pattern is typical for the single uncorrelated bilayer of
unilamellar vesicles. The single broad peak observed in the
scattering pattern is related to the bilayer thickness. Thus, a one-
dimensional thickness distance distribution function pt(r) was
calculated and revealed a cross-sectional phospholipid head-
group distance of ∼4.2 nm (Fig. 2B). Interestingly, the pt(r)
function shows a small side maximum at higher r-values. This
side maximum probably arises from the PEG-chains, which
protrude from the phospholipid bilayer as less densely packed
hydrophilic shell [29]. At a concentration of 5 mol% DSPE-
PEG2000 the PEG-lipid chains extend 4.5 to 6.5 nm from the
bilayer surface, depending on the lipid matrix used [29–31] and
might well contribute to the scattering pattern.
Likewise, the scattering pattern and the pt(r) function of
VIP-loaded liposomes showed no shift in the position of the
peak maxima to higher or lower scattering angles (Fig. 2A and
B). This indicates that no membrane thinning or thickening is
induced by peptide interaction and that the bilayer organization
is not perturbed by VIP association.
3.4. Secondary structure of VIP
To determine any changes in peptide conformation upon
liposomal entrapment, circular dichroism spectroscopy was
performed. The background corrected CD-spectra of free VIP in
Tris-buffer and liposome-associated VIP are shown in Fig. 3A.
In general, unfolded peptide chains show an intense minimum
in the far-UV CD spectrum near 200 nm, whereas folded
peptide chains are characterized by a minimum in the vicinity of
222 nm [32]. Thus, the pronounced differences in the spectral
characteristics are obvious. The molar ellipticity at 222 nm was
significantly increased for liposomal entrapped VIP as com-
pared to free VIP. For free VIP about 90% random coil
conformation was found whereas ∼50% α-helical content was
determined for liposomal VIP.
Fig. 3. Secondary structure of VIP. CD spectra of free VIP (0.15 mM) in Tris-
buffer (black line) and associated with liposomes (grey line) are shown. The
spectral contributions of Tris-buffer and empty liposomes, respectively, were
subtracted (A). The results of a secondary structure prediction obtained by
PSIPRED [33] are shown in (B). AA represents the amino acid sequence of VIP
for which coil (C) and helical (H) segments are predicted. The cartoon shows the
predicted helical strand as cylinder. The confidence level is shown below. A
helical wheel projection was applied for the amino acid sequence with the
highest confidence level for α-helical formation (C). Apolar amino acid residues
are shown in bold, whereas the apolar amino acids that might form an
amphipathic helix are additionally highlighted by a circle. The positively
charged amino acids are shown in bold italic.
Fig. 2. SAXS pattern of empty and VIP-loaded liposomes. Panel A shows the
funneled experimental scattering curves and the desmeared, approximated
scattering curves of empty (grey lines) and VIP-loaded (black lines) liposomes.
Panel B shows the corresponding one-dimensional thickness distribution
function pt(r) showing a maximum at r=4.2 nm indicative for the P–P
headgroup distance.
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structure prediction [33] that reveals an α-helix for the central
amino acid region spanning residues Tyr10 to Leu27 at a high
confidence level (Fig. 3B).
To assess whether VIP reveals amphipathic features we
transferred the amino acid sequence, which was suggested to
form an α-helix (residues 10–27), into an α-helical wheel
projection (Fig. 3C). The figure shows that at least six
hydrophobic amino acid residues are located on the same
surface, strongly suggesting that VIP is amphiphilic in nature.
Additionally, the six positively charged amino acids of VIP,
which are supposed to interact with the negatively charged
phospholipids of the membrane, are located on the same surface
or at least at the interface to the hydrophilic surface.
3.5. Intrinsic Trp-fluorescence and accessibility to
water-soluble quenchers
To study the interaction of VIP with the lipid membrane,
intrinsic Trp-fluorescence spectroscopywas performed. Accord-
ingly, a single Trp-residue was attached either to the N- terminus
(Trp1VIP) or the C-terminus (Trp29VIP) of VIP or inserted atposition 16 (Trp16VIP) of its amino acid sequence. The emission
spectra of free Trp-VIP solutions showed a maximum at 355 nm,
independent from the position of the Trp-residue, typical for a
monomeric peptide in aqueous solution. In contrast, liposomal-
entrapped Trp1VIP showed a significant blue shift in the
fluorescence emission maximum to 334 nm (Fig. 4A). This
behavior is characteristic for a membrane associated peptide, in
which the Trp-residue is located in a more lipophilic environ-
ment. As a control, Trp1VIP in a solution of pure PEG2000
showed no blue-shift of the emission maximum (Fig. 4A). The
spectra of liposomal- Trp16VIP and Trp29VIP, respectively, were
blue-shifted, but not as distinct as liposomal Trp1VIP. There was
rather an intensity maximum plateau, between 335 and 345 nm,
Fig. 4. Fluorescence data for free- and liposomal-VIP. Fluorescence spectra of
Trp-VIP are shown as a function of normalized intensities (A). The
concentration of the Trp-VIP solutions was 10 μM. Free Trp-VIP in Tris-buffer
(Δ) as well as in a solution of PEG 2000 (×) showed a maximum in emission
intensity at 355 nm. A pronounced shift of the emission intensity maximum to
334 nm is recorded for Trp1VIP (●). For Trp16VIP (○) and Trp29VIP (□) broad
intensity maxima are observed. (B) Stern–Volmer plot of the acrylamide
quenching data of free Trp1VIP in Tris-buffer (▵) and in a solution of PEG2000
(×) and liposomal Trp1VIP (●), Trp16VIP (○) and Trp29VIP (5). The
acrylamide concentration was varied between 0.02 and 0.15 M. Intensity values
were taken at the maximum of emission observed at 355 nm for free Trp-VIP in
Tris-buffer and PEG2000 solution, respectively, and at 334 nm for all liposomal-
entrapped Trp-VIP-species.
Fig. 5. Vasorelaxation efficiency and relaxation kinetics. Panel A shows the
values of the maximal relaxation in % of 100% precontraction with
phenylephrine obtained for the pairwise comparison of free VIP with
liposomal-associated VIP (n=13 pairs). Panel B demonstrates the time period
in seconds between administration of VIP and attainment of maximal relaxation
for the pairwise comparison of free VIP with liposomal-associated VIP shown in
panel A. Each pair is plotted with a specific symbol connected by a straight line.
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data we assume that Trp16VIP and Trp29VIP are attached to the
membrane, but do not stick into it.
To determine the accessibility of the Trp-residues, we have
added the water-soluble quencher acrylamide. The Stern–
Volmer quenching constants were determined according to Eq.
(2) from the data shown in Fig. 4B. The Ka-values of the three
Trp–VIP species in Tris-buffer as well as for Trp1VIP in
PEG2000 solution were nearly the same (Ka=15.2 M
−1,16.2
M−1, 17.6 M−1 and 16.2 M−1 for Trp1VIP, Trp16VIP, Trp29VIP
and Trp1VIP in PEG2000 solution, respectively). In contrast, a
decrease in Ka values was observed for all liposomal Trp–VIP
species. Namely, Ka=2.7 M
−1, 3.1 M−1 and 4.9 M−1 for
liposomal Trp1VIP, Trp16VIP and Trp29VIP, respectively, being
most pronounced for Trp1VIP. Taken together, these data clearly
reveal that liposomal VIP is shielded by the lipid bilayer and/orthe PEG-surface layer and is therefore less accessible to the
quencher as compared to free Trp-VIP. A pure PEG2000
solution without liposomes had no shielding effect at all.
3.6. Acyl chain mobility
To investigate whether VIP penetrates into the phospholipid
bilayer and thereby affects the mobility of the acyl chains we
incorporated a spin label in our liposomal formulation. The spin
label 5-DSA probes the acyl chain region close to the
phospholipid headgroups.
By examination of the spectra, values of the inner and outer
hyperfine splittings were determined and order parameters
S=0.577±0.002, 0.578±0.001 and 0.577±0.002 (n=3) for
empty, Trp-VIP- and VIP-loaded liposomes, respectively, were
calculated. The fact that the order parameters are virtually
identical indicates that the acyl chain mobility is not influenced
by peptide loading.
3.7. Vasorelaxation efficiency and kinetics
Vasorelaxation efficiency expressed as percent of maximal
relaxation (precontraction value taken as 100%) and relaxation
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in an ex vivo arterial model system performing a pairwise
comparison using the same artery. This strategy was chosen
to eliminate variations between different arterial preparations.
The maximal relaxation observed for free- and liposomal-VIP
(34.1±2.1% and 37.8±4.5%, respectively; n=13 pairs ) was
shown not to be significantly different (p>0.1). In contrast, the
kinetics, i.e. the time between VIP administration and attaining
of the maximal relaxation was significantly (p<0.001) delayed
for liposomal-associated VIP ( t=1002±115 s) compared to
free VIP ( t=418±45 s; n=13 pairs). The single values for the
relaxation efficiency and kinetics used for the pairwise com-
parison are shown in Fig. 5A and B, respectively. As control,
empty liposomes showed no relaxation activity.
4. Discussion
Polymer-grafted unilamellar liposomes were made by the
thin-film rehydration method using a ternary mixture of
phospholipid species. The lipid mixture was composed of a
zwitterionic phosphatidylcholine (POPC) as lipid matrix, a
PEGylated lipid (DSPE-PEG2000) to obtain sterical stabiliza-
tion, and an anionic lysolipid (lyso-PG). Amongst a number of
stealth liposomal formulations suggested for drug delivery
purposes in the literature (for a comprehensive review see [13]),
our formulation is exceptional mainly due to the addition of the
negatively charged lysolipid. We decided to use lyso-PG for
several reasons. First, the acidic headgroups confer an enhanced
negative surface charge to the particle that causes electrostatic
repulsion of bilayers. This special feature favors the formation
of unilamellar rather than multilamellar vesicles, preferentially
formed by phosphatidylcholine. Second, the negative charge of
phosphatidylglycerols causes electrostatic attraction of cationic
peptides and, in our special case, facilitates efficient peptide
loading through peptide–membrane interaction. Third, lysoli-
pids – due to the mono-acyl chain – adopt an inverted-cone
shape. Thus, lysolipids have a higher cross-section of the
headgroups compared to the fatty acid chain region and
maintain a spherical bilayer arrangement by conferring a
positive membrane curvature. Hence, a film of this lipid
mixture self-assembles upon hydration to unilamellar liposomes
with about 95% of the liposomes in a size range up to 200 nm.
This particle size distribution would allow for a direct transport
of the liposomes to the lower alveolar regions [21,34] without
further manipulations of the liposomes. Consequently, treat-
ment by size extrusion is not necessary, although a small
subpopulation of particles with sizes up to 550 nm is present in
the unextruded preparation. The latter contribution might well
be caused by the presence of some rod-like particles, as the
algorithm used for the calculation of average size distribution
does not distinguish between spherical or rod-like particles.
It is already known that with increasing concentrations of
PEG-lipids a transition from spherical vesicles to disks and
finally to micellar phases occurs [17,31]. For example, worm-
like micelles were reported by Edwards et al. [35] for a binary
system consisting of PEG-lipids and egg phosphatidylcholine at
molar concentrations above 15 mol% PEG-lipids. At higherPEG-lipid concentrations a final conversion from rod-like
micellar structures to spherical micelles takes place [36].
However, for the liposomal formulation reported in this study,
the PEG2000-lipid concentration was limited to 5 mol%, a
concentration at which DSPE-PEG2000 lipids are already in the
so-called brush regime, in which neighboring PEG coils interact
laterally, but the phospholipids still form a closed bilayer
structure [29]. Indeed, by TEMmeasurements we could confirm
that the liposomes are essentially spheroidal and hollow,
although a small fraction of elongated tubular particles was
seen in the images. In support, SAXS data showed an
uncorrelated bilayer structure without any indication for a
non-lamellar phase behavior or for a regular alignment of
multilayers.
VIP was associated to the liposomes at a molar ratio of
∼0.004 mole VIP / mole phospholipid. For a spherical single
bilayer nanoparticle with an average diameter of about 90 nm,
which has an outer hydrophilic PEG2000 surface layer in the
brush regime with a thickness of about 4.5 nm [29] and a
phospholipid bilayer thickness of 4.2 nm, we can estimate the
number of lipid molecules that form one vesicle. Assuming an
average cross-sectional membrane surface area of 0.65 nm2 for
lipids in the fluid phase [37], we have calculated a total number
of approximately 60000 lipid molecules for one vesicle,
equivalent to about 200 VIP molecules/liposome. However,
this value should not be considered as an upper limiting rate, but
corresponds to the loading conditions investigated in this study.
Importantly, the peptide concentration used here is in a range
suited for treatment of lung hypertension, in which the daily
administration of 200 μg free VIP via inhalation is required [6].
This value would correspond to a medication of about 400 μl of
our formulation per day, however, the therapeutic dose of VIP
might well be reduced due to protective effects of the liposomes.
In our system we have performed passive peptide loading,
which means, that the formation of liposomes takes place in the
presence of the peptide. In this way, we have achieved a
quantitative loading of VIP, which could not be separated from
the liposomes by column chromatography. However, the
question arises whether VIP is encapsulated in the aqueous
interior of the vesicle or is associated with the lipid membrane.
As it is known that VIP interacts with phospholipids [38–40] it
might well align along both the inner and outer leaflet of the
bilayer. Such an interaction would be mediated primarily by
electrostatic attractions between the polar amino acid residues
and the negatively charged phospholipid headgroups of phos-
phatidylglycerol or/and the negative charge of the phosphate
group of PEG-lipids. Additionally, VIP might penetrate the
bilayer, stabilized in part by the hydrophobic effect.
To address this issue we have performed a fluorescence
study to investigate membrane association properties of VIP.
For these experiments we have used single Trp-modified VIP
species with the Trp residue being located at different positions
along the amino acid sequence. These data indicate that the
N-terminal domain of VIP sticks in the membrane and becomes
located in a non-polar environment while the central α-helical
part and the C-terminal random coiled region are still shielded
but not that strong. The protective effect of a polymer coat was
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activation in plasma or by trypsin in vitro [41,42]. By analogy, a
similar behavior is expected for endopeptidase-modulated
degradation of liposomal-VIP in the airways [8,9]. Thus,
apart from inducing unilamellarity, the rationale for the
incorporation of PEGylated lipids in our formulation was to
protect the surface-associated peptide from degradation, rather
than to prolong the life-time of the liposome itself. Although,
one could speculate that the PEG-coat might be advantageous
to reduce liposomal uptake by alveolar macrophages and to
diminish phagocytosis.
Besides, we suppose a dual distribution of VIP within the
inner and outer leaflet of the liposomes with internally
entrapped VIP being completely protected against enzymatic
degradation. In this case, surface-associated VIP would be
recognized by its receptor first. Entrapped VIP would be
released and bound later on upon liposomal degradation. This
mechanism could be advantageous for medical applications as a
retarded relaxation effect for VIP could be achieved. Indeed, our
data from ex vivo experiments on active lung arteries displayed
a retarded dilatation effect for liposomal-VIP as compared to
free VIP.
Despite the association of VIP with the lipophilic environ-
ment of the liposomes, we could not detect a significant effect of
VIP on the bilayer arrangement. At least at the given lipid to
peptide molar ratio neither the bilayer thickness nor the mobility
of the phospholipid acyl chains were affected by VIP. One
possible explanation could be that the phospholipid acyl chains
are not very tightly packed due to the presence of lysolipids.
This is supported by the relatively low value determined for the
order parameter, which might also reflect some lateral
separation of lipid components. In view of the 250-fold excess
of lipid molecules the insertion of VIP, which is probably
restricted to the interfacial headgroup region, has no impact on
the local order parameter of the acyl chains. Likewise, some gap
caused by peptide penetration has no appreciable effect on
bilayer thickness and some local minor pertubations caused by
peptide penetration might be smoothed by global averaging of
data.
Our CD data showed that VIP exhibits a conformational
change from an unordered random coil structure in aqueous
solution to α-helical in liposomes. Such a conformational
conversion of VIP was already reported by other groups
[42,43] and seems to be mediated by negative charges. Thus,
electrostatic attraction of the positively charged peptide by
negatively charged phospholipid headgroups is supposed to
be the driving force for helix formation subsequently
stabilized by the hydrophobic effect through membrane
anchoring.
Molecular modeling has shown that VIP could form an α-
helix, spanning the central amino acid residues from Val5 to
Asn24 with random coiled N- and C-terminus [44]. These data
were confirmed by a recent NMR study that describes Thr7–
Asn24 as central helical element [22]. Consistently, the
secondary structure prediction performed in this study reveals
an α-helical region starting from Tyr10, with high prediction
confidence. A helical wheel projection of this region clearlyshows an asymmetrical distribution of polar and apolar residues
of VIP. Thereby, hydrophobic and hydrophilic residues
segregate on opposing sides of the helix to form an amphipathic
helix, which is a common feature of many membrane-active
peptides [45–47]. Notably, in our cylindrical projection along
the helix axis most of the positively charged lysine and arginine
residues, which are supposed to interact with the acidic
phospholipids, are located at the same side as the hydrophobic
residues.
By receptor binding studies it was outlined that the important
amino acids for receptor binding are distributed along the
peptide chain from position 1 to 26 [44]. Similarly, docking
experiments of VIP to VPAC1 show the direct involvement of
the amino acid sequence 6 to 28 converted in an α-helical
conformation in receptor binding. The N-terminal segment is
largely disorded as shown by NMR [22] and forms a bent
conformation as found by computational methods on amino
acids 1 to 11 using simulated annealing [48]. This N-terminal
region was suggested to interact independently with a second
receptor domain [22]. In our study we found that this segment is
trapped in the bilayer, but might become released upon receptor
binding. In any case, the helical conformation relevant for
receptor interaction is induced and stabilized by lipid interac-
tion, whereas the helical part of VIP is most probably located
parallel to the membrane. These α-helical stabilizing properties
of negatively charged vesicles could explain the higher receptor
activity reported for liposomal-VIP [38,49] as well as the
pronounced vasodilatory effect exerted in peripheral micro-
circulation [40,50]. These data are also supported by our results
on the relaxation behavior of active lung arteries in the presence
of VIP. These experiments clearly demonstrate that liposomal-
associated VIP is set free in the course of receptor binding to
trigger the observed vasodilation with comparable efficiency as
free VIP. However, the time point of maximal relaxation is
significantly delayed by liposomes indicating a retarded effect
on vasorelaxation. Nevertheless, it has to be mentioned that the
lung artery model system cannot reflect directly the in vivo
situation after aerosolic application.
In summary, for our approach we have prepared liposomes
which form stable unilamellar bilayer spheres in a size range to
be used for aerosolic delivery to the lung without further
manipulations [21,34].
The polymer-grafted liposomes were able to accommodate
reasonable amounts of active VIP to be considered for medical
treatment of PPH patients [6].
In addition, the interaction mechanisms of VIP with lipid
membranes were thoroughly investigated and the structural data
might be helpful for studies on receptor binding and provide
useful information for further developments of therapeutical
applications of this neuropeptide.
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